SCA
REGN icon

Signpost Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Signpost Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-43,326
Closed -$13M – 16
2014
Q1 		$13M Buy
+43,326
New +$13.3M 5.52% 9

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Signpost Capital Advisors's REGN Position: Q2 2014 in Review

Signpost Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2014, closing a stake of 43,326 shares — an estimated $13M sold.

Signpost Capital Advisors first reported a position in REGN in Q1 2014 and held it in 1 quarter. The position peaked at $13M in Q1 2014. 447 funds tracked by Wall St. Rank hold REGN as of Q2 2014.

  • Signpost Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Signpost Capital Advisors sold 43,326 Regeneron Pharmaceuticals shares in Q2 2014, an estimated $13M.
  • Signpost Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Signpost Capital Advisors's Regeneron Pharmaceuticals position peaked at $13M in Q1 2014.
  • 447 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2014.

Based on Signpost Capital Advisors's 13F filing for Q2 2014, filed 13 Aug 2014.